Efficacy and safety of tribendimidine vs praziquantel against Opisthorchis viverrini in Laos: An open-label, randomised, non-inferiority, phase 2 trial
The Lancet Infectious Diseases Feb 01, 2018
Sayasone S, et al. - In participants with O viverrini infection, the efficacy and safety of a single, oral dose of tribendimidine were compared with praziquantel administered in two doses. Observations revealed that compared to praziquantel, tribendimidine had a slightly lower cure rate and was not non-inferior. However, tribendimidine showed a similar egg reduction rate to praziquantel and resulted in fewer adverse events. Thereby suggesting that it might complement praziquantel in O viverrini control programmes, particularly in settings co-endemic for hookworm.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries